Perrigo 2026: Revenue $988.6M, EPS ($0.2) — 10-Q Summary
Perrigo reported 2026 nine-month net sales of $988.6M, down 5.2% YoY, and a net loss of $27.5M, compared to a net income of $7.5M in the prior year. Diluted loss per share was $0.2, versus earnings of $0.05. The decline was attributed to soft consumer demand, lower retailer inventories, and the sale of the Dermacosmetics business. Perrigo plans to sell its Infant Formula business for up to $175M and expects $80M-$100M in annual savings from a two-year efficiency program.
How this was made
The 30-second read
Why it matters
The earnings miss and announced workforce reduction signal short‑term challenges but also a strategic cost‑cutting plan.
Market read
Earnings release is a primary catalyst for PRGO; investors will reassess valuation based on loss and cost‑saving initiatives.
What to watch
Efficiency program targeting up to $100 M in savings may mitigate the loss in later quarters.
Background
Perrigo's 10‑Q filing provides the first public disclosure of its 2026 nine‑month financial performance.
Ticker impact
Perrigo disclosed its 2026 nine‑month results showing revenue down 5.2% and a net loss of $27.5 M, a fresh earnings release.
downward pressure as investors price in the earnings miss and loss
Earnings miss with a sizable net loss is a clear negative catalyst for a mid‑cap stock.
Market effects
Consumer health segment may see broader scrutiny as demand softens.
U.S. consumer‑goods investors may adjust exposure to similar firms.
Limited to companies with comparable product lines; no broad macro effect.
Counterpoint
The sale of the infant‑formula business could unlock value and improve margins over time.
Key entities
- companyPerrigo Co plc
Consumer health products manufacturer reporting 2026 nine‑month results.
